AstraZeneca stock (US6549022043): Q1 earnings beat fuels analyst upgrades

AstraZeneca delivered first-quarter results above consensus on May 11, 2026, with $2.58 EPS and $15.29 billion revenue, prompting multiple analyst rating increases and a 14.91% upside forecast.

AstraZeneca PLC reported first-quarter 2026 earnings that exceeded analyst expectations, posting earnings per share of $2.58 against a consensus estimate of $2.52 and revenue of $15.29 billion versus $14.93 billion anticipated, according to ad-hoc-news as of May 11, 2026. The earnings beat has triggered positive analyst reactions, with multiple firms issuing or reiterating buy ratings and raising price targets.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AstraZeneca PLC
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: United Kingdom
• Core markets: Oncology, cardiovascular, respiratory, and immunology
• Key revenue drivers: Oncology portfolio, specialty care products
• Home exchange/listing venue: NYSE (AZN); London Stock Exchange
• Trading currency: USD

AstraZeneca: core business model

AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and biopharmaceuticals, focusing on innovative therapies for global markets. The company's portfolio spans multiple therapeutic areas, with oncology representing the largest revenue contributor at 42.6% of net sales, followed by cardiovascular, renal and metabolic diseases at 23%, and respiratory and autoimmune diseases at 14.7%, according to MarketScreener as of May 11, 2026.

Q1 2026 financial performance and analyst sentiment

The first-quarter revenue of $15.29 billion reflects broad-based growth across therapeutic areas, demonstrating the strength of both established and newer products in the company's portfolio. The earnings beat has led to analyst upgrades, with Citigroup raising its price target to £180, signaling confidence in the company's growth trajectory. Wall Street sentiment appears mostly positive, with a consensus rating of Moderate Buy and a target price of $205.33, implying approximately 14.91% upside from current levels, according to MarketBeat as of May 11, 2026.

AstraZeneca's operational metrics underscore financial strength, with a return on equity of 30.86% and a net margin of 17.19% for the quarter. The company's full-year 2025 total revenue reached $58.739 billion, up 8% at constant rates, demonstrating sustained momentum heading into 2026.

US investor relevance and market position

US investors gain direct exposure to AstraZeneca through its NYSE listing under the ticker AZN, making it accessible to American equity portfolios. As a leading global pharmaceutical company, AstraZeneca plays a significant role in the US healthcare market, with its oncology and specialty care products serving millions of American patients. The company's strong operational performance and analyst confidence reflect its competitive positioning within the global pharmaceutical sector.

Conclusion

AstraZeneca's first-quarter 2026 earnings beat and subsequent analyst upgrades underscore the company's operational momentum and market position within the global pharmaceutical sector. The 14.91% upside forecast from current levels reflects analyst confidence in the company's ability to sustain growth across its therapeutic portfolios. US investors with exposure to the healthcare sector through the NYSE-listed AZN ticker gain access to a diversified pharmaceutical company navigating global trends effectively.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.